Compare TNON & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | OGEN |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.8M |
| IPO Year | 2021 | 2010 |
| Metric | TNON | OGEN |
|---|---|---|
| Price | $4.52 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 30.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | N/A |
| Revenue This Year | $65.95 | N/A |
| Revenue Next Year | $50.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.13 | $0.48 |
| 52 Week High | $17.84 | $1.45 |
| Indicator | TNON | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 37.55 |
| Support Level | $0.56 | $0.49 |
| Resistance Level | $7.15 | $0.59 |
| Average True Range (ATR) | 1.29 | 0.02 |
| MACD | -0.37 | -0.00 |
| Stochastic Oscillator | 0.86 | 17.17 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.